GlassScriptPhysician profile
Heather Marie Shields
NPI 1871599076
$4,141.70
in general payments reported to CMS, 2019-2025
26 companies · $884 in 2025
The $884 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,367 · 2022: $664 · 2023: $322 · 2024: $905 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,110.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,425.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $473.34 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $320.03 | 2021-2025 | Airsupra, Breztri |
| Amgen INC. | $272.40 | 2021-2025 | Repatha, Evenity, Prolia |
| Pfizer INC. | $270.57 | 2021-2025 | |
| Exact Sciences Corporation | $196.73 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $191.95 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $164.60 | 2021-2025 | |
| Amarin Pharma, INC. | $127.78 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $106.10 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.65 | 2021 | |
| Janssen Pharmaceuticals, INC | $82.21 | 2021-2022 | |
| Daiichi Sankyo INC. | $76.51 | 2021 | |
| Esperion Therapeutics, INC. | $76.34 | 2021 | |
| Theratechnologies INC. | $50.03 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $28.51 | 2023 | Seglentis |
| Astellas Pharma US INC | $28.40 | 2024 | Veozah |
| Eisai INC. | $22.53 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $21.90 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.59 | 2025 | Caplyta |
| Dexcom, INC. | $20.00 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $18.61 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $14.34 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $14.18 | 2023 | Prehevbrio |
| E.R. Squibb & Sons, L.L.C. | $12.66 | 2021 | |
| Gilead Sciences, INC. | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.